DE60000288D1 - Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten - Google Patents

Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten

Info

Publication number: DE60000288D1
Authority: DE; Germany
Prior art keywords: human insulin; modified; acylated; formulations; formulations containing
Prior art date: 1999-01-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60000288T

Other languages

English (en)

Other versions

DE60000288T2 (de

Inventor

Kingman Ng

Shun Li

Alan Watts

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-26

Filing date

2000-01-26

Publication date

2002-08-29

2000-01-26 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2002-08-29 Publication of DE60000288D1 publication Critical patent/DE60000288D1/de

2003-01-16 Application granted granted Critical

2003-01-16 Publication of DE60000288T2 publication Critical patent/DE60000288T2/de

2020-01-27 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 4
238000009472 formulation Methods 0.000 abstract 3
239000007864 aqueous solution Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
101500025353 Homo sapiens Insulin A chain Proteins 0.000 abstract 1
101500025354 Homo sapiens Insulin B chain Proteins 0.000 abstract 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
125000005313 fatty acid group Chemical group 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DE60000288T 1999-01-26 2000-01-26 Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten Expired - Fee Related DE60000288T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11729199P	1999-01-26	1999-01-26
PCT/US2000/001627 WO2000043034A2 (en)	1999-01-26	2000-01-26	Monodisperse hexameric acylated insulin analog formulations

Publications (2)

Publication Number	Publication Date
DE60000288D1 true DE60000288D1 (de)	2002-08-29
DE60000288T2 DE60000288T2 (de)	2003-01-16

Family

ID=22372048

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60000288T Expired - Fee Related DE60000288T2 (de)	1999-01-26	2000-01-26	Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten

Country Status (9)

Country	Link
EP (1)	EP1146896B1 (de)
JP (1)	JP2002535287A (de)
AT (1)	ATE220917T1 (de)
AU (1)	AU2624400A (de)
DE (1)	DE60000288T2 (de)
DK (1)	DK1146896T3 (de)
ES (1)	ES2180511T3 (de)
PT (1)	PT1146896E (de)
WO (1)	WO2000043034A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6835802B2 (en)	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
ATE496064T1 (de) *	2002-05-07	2011-02-15	Novo Nordisk As	Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
PL377813A1 (pl)	2002-11-26	2006-02-20	Biocon Limited	Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US7648962B2 (en)	2002-11-26	2010-01-19	Biocon Limited	Natriuretic compounds, conjugates, and uses thereof
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
EP2505593A1 (de)	2005-12-28	2012-10-03	Novo Nordisk A/S	Zusammensetzungen enthaltend acyliertes Insulin und Zink und Verfahren zur Herstellung dieser Zusammensetzungen
CN101573133B (zh)	2006-07-31	2014-08-27	诺沃-诺迪斯克有限公司	Peg化延长的胰岛素
KR101729986B1 (ko)	2006-09-22	2017-04-25	노보 노르디스크 에이/에스	프로테아제 내성 인슐린 유사체
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (de)	2007-06-13	2019-08-07	Novo Nordisk A/S	Pharmazeutische formulierung enthaltend ein insulinderivat
ES2618073T3 (es)	2008-03-14	2017-06-20	Novo Nordisk A/S	Análogos de insulina estabilizados frente a proteasas
EP2910569B1 (de)	2008-03-18	2016-10-05	Novo Nordisk A/S	Proteasestabilisierte, acylierte Insulinanaloga
BRPI0919946A2 (pt)	2008-10-30	2016-02-16	Novo Nordisk As	tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
RU2013123515A (ru)	2010-10-27	2014-12-10	Ново Нордиск А/С	Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2013247047A1 (en)	2012-04-11	2014-10-23	Novo Nordisk A/S	Insulin formulations
KR102205512B1 (ko)	2012-11-13	2021-01-20	아도시아	치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
WO2014177623A1 (en)	2013-04-30	2014-11-06	Novo Nordisk A/S	Novel administration regime
PL3055325T3 (pl)	2013-10-07	2018-06-29	Novo Nordisk A/S	Nowa pochodna analogu insuliny
AR102869A1 (es)	2014-12-16	2017-03-29	Lilly Co Eli	Composiciones de insulina de rápida acción
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
HRP20221324T1 (hr) *	2016-12-16	2022-12-23	Novo Nordisk A/S	Farmaceutski pripravci koji sadrže inzulin
US11207384B2 (en)	2017-06-01	2021-12-28	Eli Lilly And Company	Rapid-acting insulin compositions
EP3668892A1 (de)	2017-08-17	2020-06-24	Novo Nordisk A/S	Neuartige acylierte insulinanaloga und verwendungen dafür
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
JP7518149B2 (ja)	2019-07-12	2024-07-17	ノヴォノルディスクアー／エス	高濃度インスリン製剤
WO2021033066A1 (en) *	2019-08-16	2021-02-25	Lamark Biotech Pvt Limited	A formulation of insulin based on crystal-seeding in hydrogels and method thereof
WO2025061146A1 (zh) *	2023-09-20	2025-03-27	上海迈晋生物医药科技有限公司	一种人胰岛素类似物融合蛋白的药物组合物及其医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4404380B2 (ja) *	1996-06-20	2010-01-27	ノボノルディスクアクティーゼルスカブ	ＮａＣｌ含有インスリン製剤
AU5749198A (en) *	1997-02-07	1998-08-26	Novo Nordisk A/S	Crystallisation of proteins
JP2002500196A (ja) *	1998-01-09	2002-01-08	ノヴォノルディスクアクティーゼルスカブ	安定化させたインスリン組成物

2000
- 2000-01-26 AT AT00904496T patent/ATE220917T1/de not_active IP Right Cessation
- 2000-01-26 DE DE60000288T patent/DE60000288T2/de not_active Expired - Fee Related
- 2000-01-26 PT PT00904496T patent/PT1146896E/pt unknown
- 2000-01-26 ES ES00904496T patent/ES2180511T3/es not_active Expired - Lifetime
- 2000-01-26 AU AU26244/00A patent/AU2624400A/en not_active Abandoned
- 2000-01-26 WO PCT/US2000/001627 patent/WO2000043034A2/en active IP Right Grant
- 2000-01-26 EP EP00904496A patent/EP1146896B1/de not_active Expired - Lifetime
- 2000-01-26 DK DK00904496T patent/DK1146896T3/da active
- 2000-01-26 JP JP2000594487A patent/JP2002535287A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PT1146896E (pt)	2002-10-31
AU2624400A (en)	2000-08-07
ATE220917T1 (de)	2002-08-15
EP1146896A2 (de)	2001-10-24
DK1146896T3 (da)	2002-09-02
DE60000288T2 (de)	2003-01-16
EP1146896B1 (de)	2002-07-24
ES2180511T3 (es)	2003-02-16
WO2000043034A3 (en)	2000-12-28
JP2002535287A (ja)	2002-10-22
WO2000043034A2 (en)	2000-07-27

Publication	Publication Date	Title
DE60000288D1 (de)	2002-08-29	Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
EP1808438A3 (de)	2008-12-24	Reinigung und Stabilisierung von Peptiden und Proteinen in pharmazeutischen Wirkstoffen
HU906177D0 (en)	1991-08-28	Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
WO2002043750A8 (en)	2003-12-31	Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
HUP0100243A2 (hu)	2001-08-28	Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
IL72033A0 (en)	1984-10-31	Oral pharmaceutical compositions containing antidiabetic agents
DE58901401D1 (de)	1992-06-17	Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
EP0911021A3 (de)	2001-08-01	Methoden und Zusammensetzungen für feine Linien und/oder Falten
AU2840789A (en)	1989-05-04	Continuous release pharmaceutical compositions
AU563642B2 (en)	1987-07-16	Oral antidiabetic composition
PT1098643E (pt)	2004-05-31	Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
WO1996024370B1 (en)	1996-09-19	Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
KR950700326A (ko)	1995-01-16	파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
CA2522146A1 (en)	2005-10-13	Uptake of macromolecules
BR9607541A (pt)	1997-12-23	Tratamento de doenças que tem por causa o fator de crescimento da citoquina
AU7655098A (en)	1998-12-08	Somatostatin and somatostatin agonists for decreasing body weight
Yaegaki et al.	1989	The effect of mouthwash on oral malodour production
HU896916D0 (en)	1991-08-28	Process for producing medical preparation for treating toxoplasmosis
AU4519289A (en)	1991-05-16	Medicament for the treatment of cryptosporidiosis
PT97878A (pt)	1992-12-31	Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais

Legal Events

Date	Code	Title	Description
2003-08-21	8364	No opposition during term of opposition
2004-11-11	8339	Ceased/non-payment of the annual fee